title: Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
abstract: Whereas transplantable tumors can be readily cured with immunotherapeutic approaches, similar therapies in cancer patients have been less effective. This difference may be explained by an immunosuppression resulting from the presence of a slowly growing primary tumor in the patient, whereas the immune system in a mouse with a rapidly proliferating transplantable tumor would be less affected. As a more appropriate model to the immune dysfunction in patients, slowly progressing primary tumors were induced by the carcinogen methylcholanthrene (MC) in mice. Their ability to induce immunosuppression in T cells and natural killer (NK) cells was compared to that of rapidly growing transplanted MC-induced tumors. The results demonstrate that mice bearing primary MC tumors had significantly diminished T-cell and NK-cell functions, impaired capacity to produce Th1 cytokines, and markedly reduced levels of the signal-transducing zeta chain in T cells and NK cells, similar to that described in cancer patients. Moreover, a substantial number of CD8+ T cells in mice with large primary MC tumors were undergoing apoptosis, correlating with alterations in CD4/CD8 ratios. In contrast, T cells and NK cells from mice bearing rapidly growing transplanted tumors were only marginally affected. These findings could explain the apparent discrepancy between the consistent findings of a diminished immune response and alterations in signal transduction in cancer patients as compared to the less reproducible observations in murine transplantable tumors. In addition, they could explain the differences in the high efficacy of immunotherapy in mice with transplantable tumors and the low therapeutic results in cancer patients.
authors.affiliation: Immune and Genetherapy Laboratory, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Horiguchi
authors.forename: M
authors.initials: M
authors.lastname: Petersson
authors.forename: T
authors.initials: T
authors.lastname: Nakazawa
authors.forename: M
authors.initials: M
authors.lastname: Kanda
authors.forename: A H
authors.initials: AH
authors.lastname: Zea
authors.forename: A C
authors.initials: AC
authors.lastname: Ochoa
authors.forename: R
authors.initials: R
authors.lastname: Kiessling
mesh_terms: D000818:Animals; D017209:Apoptosis; D017252:CD3 Complex / Q000276:immunology; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D002273:Carcinogens; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D007108:Immune Tolerance; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D008748:Methylcholanthrene; D051379:Mice; D009368:Neoplasm Transplantation; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000096:biosynthesis; D012513:Sarcoma, Experimental / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D015398:Signal Transduction; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology
chemical_list: D017252:CD3 Complex; D002273:Carcinogens; D016207:Cytokines; D016692:Receptors, Antigen, T-Cell, gamma-delta; D008748:Methylcholanthrene